

International journal of pharm.
DUP - General Collection
W1 IN771T
v. 384, no. 1-2
Jan. 15 2010


15 JANUARY 2010

ISSN 0378-5173

ELSEVIER

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Special section on:
**PHARMACEUTICAL
NANOTECHNOLOGY**



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

INTERNATIONAL JOURNAL OF PHARMACEUTICS

www.elsevier.com/locate/ijpharm

AIMS AND SCOPE

The *International Journal of Pharmaceutics* publishes innovative papers, reviews, mini-reviews, rapid communications and notes dealing with physical, chemical, biological, microbiological and engineering studies related to the conception, design, production, characterisation and evaluation of drug delivery systems in vitro and in vivo. 'Drug' is defined as any therapeutic or diagnostic entity, including oligonucleotides, gene constructs and radiopharmaceuticals.

Areas of particular interest include: pharmaceutical nanotechnology; physical pharmacy; polymer chemistry and physical chemistry as applied to pharmaceutics; excipient function and characterisation; biopharmaceutics; absorption mechanisms; membrane function and transport; novel routes and modes of delivery; responsive delivery systems, feedback and control mechanisms including biosensors; applications of cell and molecular biology to drug delivery; prodrug design; bioadhesion (carrier-ligand interactions); and biotechnology (protein and peptide formulation and delivery).

EDITORIAL POLICY

The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.

Editor-in-Chief:

A.T. Florence The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK Email: Ataylorflorence@aol.com

Editors:

Europe, Africa and the Near East:

G. Buckton Department of Pharmaceutics, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK
Email: ijp2gb@pharmacy.ac.uk

The Americas and Australia:

D. Burgess Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road, Storrs, CT, USA, Email: d.burgess@uconn.edu

Japan and Far East

T. Sonobe Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Shizuoka-shi 422-8526, Japan
Email: sonobe-10@gakushikai.jp

Review Editor:

All Regions

J. Siepmann College of Pharmacy, Université de Lille, 3 rue de Professeur Laguesse, 59006, Lille, France, Email: juergen.siepmann@univ-lille2.fr

Advisor:

T. Nagai Tokyo, Japan

EDITORIAL BOARD

G. Alderborn (Uppsala, Sweden)	H. Harashima (Hokkaido, Japan)	E. Shefter (San Diego, CA, U.S.A.)
M.J. Alonso (Santiago de Compostela, Spain)	L. Illum (Nottingham, U.K.)	J.D. Smart (Brighton, U.K.)
E. Allémann (Geneva, Switzerland)	M.E. Lane (London, U.K.)	K. Sugibayashi (Saitama, Japan)
D. Attwood (Manchester, U.K.)	T. Loftsson (Reykjavik, Iceland)	Y. Sugiyama (Tokyo, Japan)
K.L. Audus (Lawrence, KS, U.S.A.)	P. Macheras (Athens, Greece)	M.D. Ticehurst (Sandwich, U.K.)
G. Borchard (Geneva, Switzerland)	Y. Maitani (Tokyo, Japan)	I.G. Tucker (Dunedin, New Zealand)
H.-K. Chan (Sydney, NSW, Australia)	G.P. Martin (London, U.K.)	I.F. Uchebu (Glasgow, U.K.)
W.N. Charman (Parkville, Australia)	C.D. Melia (Nottingham, U.K.)	K. Uekama (Kumamoto, Japan)
J.H. Collett (Manchester, U.K.)	A.K. Mitra (Kansas City, MO, U.S.A.)	A. Urtti (Helsinki, Finland)
D.Q.M. Craig (Norwich, U.K.)	R.H. Müller (Berlin, Germany)	G. Van den Mooter (Beerse, Belgium)
D.J.A. Crommelin (Utrecht, The Netherlands)	J.M. Newton (London, U.K.)	S.P. Vyas (Sagar, India)
F. Cui (Shenyang, P.R. China)	N. Peppas (Austin, TX, U.S.A.)	D.E. Wurster (Iowa City, IA, U.S.A.)
D. Duchêne (Châtenay-Malabry, France)	F. Podczek (London, U.K.)	S. Yalkowsky (Tucson, AZ, U.S.A.)
J.L. Ford (Liverpool, U.K.)	M. Blanco Prieto (Pamplona, Spain)	A. Yamamoto (Kyoto, Japan)
J. Hadgraft (London, U.K.)	J.P. Remon (Gent, Belgium)	
B.C. Hancock (Groton, CT, U.S.A.)	A.J. Repta (Park City, UT, U.S.A.)	

HONORARY BOARD MEMBER

W. Higuchi (Salt Lake City, UT, U.S.A.)

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editor-in-Chief

A.T. FLORENCE (London, U.K.)

Editors

G. BUCKTON (London, U.K.)

D. BURGESS (Storrs, CT, U.S.A.)

T. SONOBE (Shizuoka-shi, Japan)

Review Editor

J. SIEPMANN (Lille, France)

Advisor

T. NAGAI (Tokyo, Japan)

Editorial Board

G. ALDERBORN (Uppsala, Sweden)

E. ALLÉMANN (Geneva, Switzerland)

M.J. ALONSO (Santiago de Compostela, Spain)

D. ATTWOOD (Manchester, U.K.)

K.L. AUDUS (Lawrence, KS, U.S.A.)

G. BORCHARD (Geneva, Switzerland)

H.-K. CHAN (Sydney, NSW, Australia)

W.N. CHARMAN (Parkville, Australia)

J.H. COLLETT (Manchester, U.K.)

D.Q.M. CRAIG (Norwich, U.K.)

D.J.A. CROMMELIN (Utrecht, The Netherlands)

F. CUI (Shenyang, P.R. China)

D. DUCHÈNE (Châtenay-Malabry, France)

J.L. FORD (Liverpool, U.K.)

J. HADGRAFT (London, U.K.)

H. HARASHIMA (Hokkaido, Japan)

L. ILLUM (Nottingham, U.K.)

M.E. LANE (London, U.K.)

T. LOFTSSON (Reykjavik, Iceland)

P. MACHERAS (Athens, Greece)

Y. MAITANI (Tokyo, Japan)

G.P. MARTIN (London, U.K.)

C.D.MELIA (Nottingham, U.K.)

A.K. MITRA (Kansas City, MO, U.S.A.)

R.H. MÜLLER (Berlin, Germany)

J.M. NEWTON (London, U.K.)

N. PEPPAS (Austin, TX, U.S.A.)

F. PODCZECK (London, U.K.)

M. BLANCO PRIETO (Pamplona, Spain)

J.P. REMON (Gent, Belgium)

A.J. REPTA (Park City, UT, U.S.A.)

E. SHEFTER (San Diego, CA, U.S.A.)

J.D. SMART (Brighton, U.K.)

K. SUGIBAYASHI (Saitama, Japan)

Y. SUGIYAMA (Tokyo, Japan)

M.D. TICEHURST (Sandwich, U.K.)

I.G. TUCKER (Dunedin, New Zealand)

I.F. UCHEGBU (Glasgow, U.K.)

K. UEKAMA (Kumamoto, Japan)

A. URTTI (Helsinki, Finland)

G. VAN DEN MOOTER (Beerse, Belgium)

S.P. VYAS (Sagar, India)

D.E. WURSTER (Iowa City, IA, U.S.A.)

S. YALKOWSKY (Tucson, AZ, U.S.A.)

A. YAMAMOTO (Kyoto, Japan)

Honorary Board Member

W. HIGUCHI (Salt Lake City, UT, USA)



ELSEVIER

Amsterdam • Boston • London • New York • Oxford • Paris • Philadelphia • San Diego • St. Louis

VOL. 384/1-2 (2010)

doi:10.1016/S0378-5173(09)00828-X

© 2010 Elsevier B.V. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier B.V., and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions).

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Sponsored Supplements and/or Commercial Reprints: For more information please contact Elsevier Life Sciences Commercial Sales, Radarweg 29, 1043 NX Amsterdam, The Netherlands; phone: (+31) (20) 485 2939/2059; e-mail: LSCS@elsevier.com

Advertising information: Advertising orders and enquiries can be sent to: Janine Castle, Elsevier Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 1865 843 844; fax: (+44) 1865 853 973; e-mail: j.castle@elsevier.com. Customers in the US and Canada can also contact: Mr Tino DeCarlo, Advertising Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; email: t.decarlo@elsevier.com

Europe and ROW: James Kenney, Print Operations Co-ordinator, Elsevier, 84 Theobalds Road, London WC1X 8RR, phone: (+44) (0) 20 7611 4117; fax: +44 (0) 20 7611 4463; e-mail: j.kenney@elsevier.com

Orders, claims, and journal enquiries: please contact the Elsevier Customer Service Department nearest you

St. Louis: Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (877) 8397126 [toll free within the USA]; (+1) (314) 4478878 [outside the USA]; fax: (+1) (314) 4478077; e-mail: JournalCustomerService-usa@elsevier.com

Oxford: Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCustomerServiceEMEA@elsevier.com

Tokyo: Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com

Singapore: Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomerServiceAPAC@elsevier.com

⊗ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)

Printed by Polestar Wheatons Ltd, Exeter, UK



Review

Transungual drug delivery: Current status

Rania Elkeeb^{a,*}, Ali AliKhan^{b,1}, Laila Elkeeb^{c,1}, Xiaoying Hui^a, Howard I. Maibach^a^a Department of Dermatology, School of Medicine, University of California, San Francisco, CA 94143-0989, USA^b School of Medicine, University of California, Davis, CA, USA^c Department of Dermatology, School of Medicine, University of California, Irvine, CA, USA

ARTICLE INFO

Article history:

Received 9 June 2009
 Received in revised form
 22 September 2009
 Accepted 1 October 2009
 Available online 9 October 2009

Keywords:

Ungual drug delivery
 Onychomycosis
 Nail penetration
 Antifungal
 Onychopharmacokinetics

ABSTRACT

Topical therapy is highly desirable in treating nail disorders due to its localized effects, which results in minimal adverse systemic events and possibly improved adherence. However, the effectiveness of topical therapies is limited by minimal drug permeability through the nail plate. Current research on nail permeation that focuses on altering the nail plate barrier by means of chemical treatments, penetration enhancers as well as physical and mechanical methods is reviewed. A new method of nail sampling is examined. Finally limitations of current unguinal drug permeability studies are briefly discussed.

© 2009 Elsevier B.V. All rights reserved.

Contents

1. Introduction.....	2
2. Topical drug delivery to the nail and available formulations.....	2
3. Human nail.....	2
4. Nail sampling.....	2
5. Enhancing nail penetration.....	3
5.1. Mechanical methods to enhance nail penetration.....	3
5.1.1. Nail abrasion.....	3
5.1.2. Nail avulsion.....	3
5.2. Chemical methods to enhance nail penetration.....	3
5.2.1. <i>N</i> -acetyl-L-cysteine and mercaptan compounds.....	3
5.2.2. 2- <i>n</i> -nonyl-1,3-dioxolane.....	3
5.2.3. Keratolytic enhancers.....	4
5.2.4. Keratinolytic enzymes.....	4
5.3. Physical methods to enhance nail penetration.....	4
5.3.1. Iontophoresis.....	4
5.3.2. Etching.....	5
5.3.3. Carbon dioxide laser.....	5
5.3.4. Hydration and occlusion.....	5
5.4. New frontiers in physical penetration enhancement.....	6
5.4.1. Lasers.....	6
5.4.2. Phonophoresis.....	6
5.4.3. Ultraviolet light.....	6
5.4.4. Photodynamic therapy of onychomycosis with aminolevulinic acid.....	6

* Corresponding author at: C/O Dr. H.I. Maibach, Department of Dermatology, School of Medicine, UCSF, 90 Medical Center Way, San Francisco, CA 9414-0989, USA. Tel.: +1 415 476 4997/738 8523; fax: +1 415 753 5304.

E-mail addresses: relkeeb@yahoo.com (R. Elkeeb), MaibachH@derm.ucsf.edu (H.I. Maibach).

¹ Rania Elkeeb, Ali AliKhan and Laila Elkeeb have contributed equally to the work.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.